title: Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.
authors.affiliation: Department of Pharmacy, University Bonn, Bonn, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Schlesinger
authors.forename: A
authors.initials: A
authors.lastname: Naggi
authors.forename: G
authors.initials: G
authors.lastname: Torri
authors.forename: R
authors.initials: R
authors.lastname: Zeisig
authors.forename: M
authors.initials: M
authors.lastname: Alexander
authors.forename: P
authors.initials: P
authors.lastname: Schmitz
authors.forename: B
authors.initials: B
authors.lastname: Casu
authors.forename: G
authors.initials: G
authors.lastname: Bendas
mesh_terms: D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D006493:Heparin / Q000031:analogs & derivatives / Q000494:pharmacology*; D006801:Humans; D039041:Integrin alpha4beta1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D008545:Melanoma / Q000473:pathology / Q000556:secondary*; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism
chemical_list: D039041:Integrin alpha4beta1; D019010:Vascular Cell Adhesion Molecule-1; D006493:Heparin